Publicacións nas que colabora con Mariano Provencio Pulla (42)

2024

  1. Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry

    Archivos de Bronconeumologia

  2. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

  3. Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry

    Lung Cancer, Vol. 190

  4. Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk

    Lung Cancer, Vol. 195

  5. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1647-1663

  6. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial

    The Lancet Oncology, Vol. 25, Núm. 11, pp. 1453-1464

  7. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049

2023

  1. Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

    ERJ Open Research, Vol. 9, Núm. 6

  2. Occupation as a risk factor of small cell lung cancer

    Scientific Reports, Vol. 13, Núm. 1

  3. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513

  4. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

    Annals of Oncology, Vol. 34, Núm. 10, pp. 920-933

2022

  1. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

    BMC Cancer, Vol. 22, Núm. 1

  2. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

    Journal of Clinical Oncology, Vol. 71

  3. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

    Journal for immunotherapy of cancer, Vol. 10, Núm. 9

2021

  1. Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study

    Translational Lung Cancer Research, Vol. 10, Núm. 10, pp. 3902-3911

  2. Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial

    Molecular Oncology, Vol. 15, Núm. 1, pp. 43-56

  3. Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the thoracic tumor registry

    PLoS ONE, Vol. 16, Núm. 6 June

  4. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

  5. Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy

    Clinical Cancer Research, Vol. 27, Núm. 21, pp. 5878-5890

  6. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

    BMC Cancer, Vol. 21, Núm. 1